Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel trevatide - Angiochem

Drug Profile

Paclitaxel trevatide - Angiochem

Alternative Names: ANG-1005; Angiopep peptide + paclitaxel conjugate – Angiochem; Angiopep-2 paclitaxel conjugate - Angiochem; GRN-1005; Paclitaxel peptide vector conjugate - Angiochem; Paclitaxel-AngioPep1-conjugate-Angiochem; SNG 1005

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AngioChem
  • Class Antineoplastics; Drug conjugates; Paclitaxels; Peptides
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Brain metastases; Glioblastoma; Glioma

Most Recent Events

  • 10 Sep 2021 Biomarkers information updated
  • 05 Aug 2019 Innovent Biologics enters into a collaboration agreement with Shenogen Pharma Group for Cancer (Combination therapy, Late-stage disease)
  • 29 May 2019 The National Medical Products Administration approves an IND for a phase II/III trial in Brain metastases (in patients with HER2-negative breast cancer) in China (9272559; 9272205)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top